Prescribing Information
... In a 12-month, placebo (vehicle nasal spray)-controlled, safety trial, 890 patients 12 years of age and older with perennial allergic rhinitis were randomized to treatment with olopatadine hydrochloride nasal solution (nasal spray) 2 sprays per nostril twice daily (445 patients) or vehicle nasal spr ...
... In a 12-month, placebo (vehicle nasal spray)-controlled, safety trial, 890 patients 12 years of age and older with perennial allergic rhinitis were randomized to treatment with olopatadine hydrochloride nasal solution (nasal spray) 2 sprays per nostril twice daily (445 patients) or vehicle nasal spr ...
DRUGDEX DRUG EVALUATIONS
... 1. Summary: Cholestyramine can bind oral anticoagulants in the gut and limit their absorption, thus impairing their activity. Separating the doses of the drugs by several hours may lessen the impact of this interaction, but because anisindione undergoes enterohepatic recirculation, time separation o ...
... 1. Summary: Cholestyramine can bind oral anticoagulants in the gut and limit their absorption, thus impairing their activity. Separating the doses of the drugs by several hours may lessen the impact of this interaction, but because anisindione undergoes enterohepatic recirculation, time separation o ...
XP13512 [()-1-([(α-Isobutanoyloxyethoxy
... ing mechanism responsible for this dose dependence is believed to be saturable absorption of gabapentin from the intestine of humans and animals by a low-capacity, solute transporter localized in the upper small intestine (Stewart et al., 1993; Uchino et al., 2002). This absorption pathway is appare ...
... ing mechanism responsible for this dose dependence is believed to be saturable absorption of gabapentin from the intestine of humans and animals by a low-capacity, solute transporter localized in the upper small intestine (Stewart et al., 1993; Uchino et al., 2002). This absorption pathway is appare ...
Pharmacological and Pharmaceutical Profile of Valsartan: A Review
... general classification system that categorises drugs with respect to their biopharmaceutical and absorption properties.In the biopharmaceutical classification system, valsartan has been classified as Class III drug with low permeability, poor metabolism and high solubility (Saydam et al., 2007). The ...
... general classification system that categorises drugs with respect to their biopharmaceutical and absorption properties.In the biopharmaceutical classification system, valsartan has been classified as Class III drug with low permeability, poor metabolism and high solubility (Saydam et al., 2007). The ...
SERETIDE ACCUHALER/DISKUS™
... Salmeterol acts locally in the lung therefore plasma levels are not an indication of therapeutic effects. In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma due to the low plasma concentrations at ...
... Salmeterol acts locally in the lung therefore plasma levels are not an indication of therapeutic effects. In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma due to the low plasma concentrations at ...
Therapeutic monitoring of vancomycin in adult patients
... use for nearly 50 years as a penicillin alternative to treat penicillinaseproducing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use ...
... use for nearly 50 years as a penicillin alternative to treat penicillinaseproducing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use ...
Understanding your BOTOX treatment Answers to questions about BOTOX
... Initial U.S. Approval: 1989 WARNING: Distant Spread of Toxin Effect See full prescribing information for complete boxed warning. The effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms ha ...
... Initial U.S. Approval: 1989 WARNING: Distant Spread of Toxin Effect See full prescribing information for complete boxed warning. The effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms ha ...
product monograph
... Pregnant Women: The safe use of topical corticosteroids during pregnancy has not been established. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at dosage levels that are similar to therapeutic doses. Some corticosteroids have been shown to be ...
... Pregnant Women: The safe use of topical corticosteroids during pregnancy has not been established. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at dosage levels that are similar to therapeutic doses. Some corticosteroids have been shown to be ...
Extended-Release Tablets, USP (SR)
... The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 subjects. The pooled analyses of placebo-controlled trials in ad ...
... The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 subjects. The pooled analyses of placebo-controlled trials in ad ...
Extended-Release Tablets, USP (SR)
... achieve steady-state blood levels of bupropion. The patient should set a “target quit date” within the first 2 weeks of treatment with bupropion hydrochloride extended-release tablets (SR). Dosing: To minimize the risk of seizure: • Begin dosing with one 150 mg tablet per day for 3 days. • Increase ...
... achieve steady-state blood levels of bupropion. The patient should set a “target quit date” within the first 2 weeks of treatment with bupropion hydrochloride extended-release tablets (SR). Dosing: To minimize the risk of seizure: • Begin dosing with one 150 mg tablet per day for 3 days. • Increase ...
TABLE OF CONTENTS - American Academy of Ophthalmology
... natural reservoir. Studies examining the presence of HSV-1 DNA in the trigeminal ganglia have determined that at least 90% of the world's population is infected with latent HSV-1 by the age of 60.8-12 However, according to a 2006 survey study, the overall seroprevalence of HSV-1 in the United States ...
... natural reservoir. Studies examining the presence of HSV-1 DNA in the trigeminal ganglia have determined that at least 90% of the world's population is infected with latent HSV-1 by the age of 60.8-12 However, according to a 2006 survey study, the overall seroprevalence of HSV-1 in the United States ...
Morphine Sulfate Extended-Release Tablets Page 1 of 22
... Accidental Ingestion Accidental ingestion of even one dose of morphine sulfate extended-release tablets, especially by children, can result in a fatal overdose of morphine [see Warnings and Precautions (5.2)]. Neonatal Opioid Withdrawal Syndrome Prolonged use of morphine sulfate extended-release tab ...
... Accidental Ingestion Accidental ingestion of even one dose of morphine sulfate extended-release tablets, especially by children, can result in a fatal overdose of morphine [see Warnings and Precautions (5.2)]. Neonatal Opioid Withdrawal Syndrome Prolonged use of morphine sulfate extended-release tab ...
SEVOFLURANE
... anesthesia, including inhalation anesthesia. Caution should be exercised in administering general anesthesia, including sevoflurane, to patients with mitochondrial disorders. Carcinogenesis and Mutagenesis Studies on carcinogenesis have not been performed. No mutagenic effect was noted in the Ames t ...
... anesthesia, including inhalation anesthesia. Caution should be exercised in administering general anesthesia, including sevoflurane, to patients with mitochondrial disorders. Carcinogenesis and Mutagenesis Studies on carcinogenesis have not been performed. No mutagenic effect was noted in the Ames t ...
Safety and Efficacy of Ranibizumab and Bevacizumab for the
... Ocular anti-vascular endothelial growth factor (VEGF) therapy represents a major breakthrough in the treatment of patients with neovascular age-related macular degeneration (nvAMD). The anti-VEGF agents, ranibizumab and bevacizumab, are both widely used in the treatment of nvAMD although bevacizumab ...
... Ocular anti-vascular endothelial growth factor (VEGF) therapy represents a major breakthrough in the treatment of patients with neovascular age-related macular degeneration (nvAMD). The anti-VEGF agents, ranibizumab and bevacizumab, are both widely used in the treatment of nvAMD although bevacizumab ...
PRODUCT MONOGRAPH Pr CLINDOXYL® ADV Gel Pr
... subjects who experienced treatment-related adverse events was low and was similar in each treatment group . No individual treatment-related adverse event was reported by more than 2 subjects (≤ 1%) within any of the treatment groups. The most frequentlyreported treatment-related adverse events were ...
... subjects who experienced treatment-related adverse events was low and was similar in each treatment group . No individual treatment-related adverse event was reported by more than 2 subjects (≤ 1%) within any of the treatment groups. The most frequentlyreported treatment-related adverse events were ...
Acute Drug Therapy for Migraine Headache
... medications). Strong recommendations were made to avoid use of butorphanol and butalbital-containing medications. Metoclopramide and domperidone were strongly recommended for use where necessary. Our analysis also resulted in the formulation of eight general acute migraine treatment strategies. Thes ...
... medications). Strong recommendations were made to avoid use of butorphanol and butalbital-containing medications. Metoclopramide and domperidone were strongly recommended for use where necessary. Our analysis also resulted in the formulation of eight general acute migraine treatment strategies. Thes ...
Poisoning and Drug Overdose
... omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each d ...
... omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each d ...
Gemcitabine 1g Powder for Solution for Infusion
... surgery has been shown. Randomised trials demonstrate that the combination of gemcitabine and cisplatin should be considered one of the more effective combinations in advanced NSCLC. In the elderly, gemcitabine is an example of a single agent of choice in NSCLC. The clinical overview adds that many ...
... surgery has been shown. Randomised trials demonstrate that the combination of gemcitabine and cisplatin should be considered one of the more effective combinations in advanced NSCLC. In the elderly, gemcitabine is an example of a single agent of choice in NSCLC. The clinical overview adds that many ...
Australian public assessment report for Dolutegravir (as sodium)
... antiretroviral therapy (ART), INIs block the action of the integrase (IN) viral enzyme required for HIV replication. Two INIs, raltegravir (RAL) and elvitegravir (EVG), have proved effective and have been approved for use in combination with other ART. However, new therapies continue to be required ...
... antiretroviral therapy (ART), INIs block the action of the integrase (IN) viral enzyme required for HIV replication. Two INIs, raltegravir (RAL) and elvitegravir (EVG), have proved effective and have been approved for use in combination with other ART. However, new therapies continue to be required ...
Extract from Clinical Evaluation Report: Ivermectin
... to apply the cream, and poor infrastructure for washing it off. Hence, rapid reinfestation may be common due to the high prevalence of scabies, overcrowding and frequent movement between households and communities. Another potential concern is the development of drug resistance when such long-runnin ...
... to apply the cream, and poor infrastructure for washing it off. Hence, rapid reinfestation may be common due to the high prevalence of scabies, overcrowding and frequent movement between households and communities. Another potential concern is the development of drug resistance when such long-runnin ...
DOVOBET® Gel
... Known hypersensitivity to DOVOBET gel (calcipotriol and betamethasone dipropionate gel), to any ingredient in the formulation or to components of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph. Ophthalmic use Patients wit ...
... Known hypersensitivity to DOVOBET gel (calcipotriol and betamethasone dipropionate gel), to any ingredient in the formulation or to components of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph. Ophthalmic use Patients wit ...
Clinical overview - WHO archives
... importantly, takes over the protecting part of the combination against re-infection with maintained clinically effective mefloquine concentrations for several weeks and thus, might delay or even prevent the emergence of resistance to both mefloquine and artesunate.7 In addition, the use of combinati ...
... importantly, takes over the protecting part of the combination against re-infection with maintained clinically effective mefloquine concentrations for several weeks and thus, might delay or even prevent the emergence of resistance to both mefloquine and artesunate.7 In addition, the use of combinati ...
HIGHLIGHTS OF PRESCRIBING INFORMATION more days. (2.3)
... Pregnancy Category C: There are no adequate and well-controlled clinical trials in pregnant women. Azelastine hydrochloride has been shown to cause developmental toxicity in mice, rats, and rabbits. ASTEPRO Nasal Spray should be used during pregnancy only if the potential benefit justifies the poten ...
... Pregnancy Category C: There are no adequate and well-controlled clinical trials in pregnant women. Azelastine hydrochloride has been shown to cause developmental toxicity in mice, rats, and rabbits. ASTEPRO Nasal Spray should be used during pregnancy only if the potential benefit justifies the poten ...
Therapeutic Monitoring of Vancomycin in Adult Patients
... clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 ...
... clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights
... propionate nasal spray [see Adverse Reactions (6.2)]. Candida Infection: In clinical trials with fluticasone propionate administered intranasally, the development of localized infections of the nose and pharynx with Candida albicans has occurred. When such an infection develops, it may require treat ...
... propionate nasal spray [see Adverse Reactions (6.2)]. Candida Infection: In clinical trials with fluticasone propionate administered intranasally, the development of localized infections of the nose and pharynx with Candida albicans has occurred. When such an infection develops, it may require treat ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.